Monthly schizophrenia therapy ‘Abilify Maintena’ launched with insurance benefit
A schizophrenia therapy whose patient drug compliance and recurrence control were improved compared to oral drugs, ‘Abilify Maintena’ will be launched this September.
Korea Otsuka Pharmaceuticals(CEO Seung-ho Moon) announced a plan to launch the drug with health insurance benefits at a press co...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
